Research progress of Wnt/β-catenin signaling pathway in tumor drug resistance

Abstract

Yi Zhigang, Zhou Kaisheng, Pu Yanchuan, Wang Xingwen, Wang Shuanke. Research progress of Wnt/β-catenin signaling pathway in tumor drug resistance[J]. Journal of International Oncology, 2016, 43(6): 455-457.

References

［1］Liu YY, Gupta V, Patwardhan GA, et al. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling[J]. Mol Cancer, 2010, 9: 145. DOI: 10.1186/1476-4598-9-145. ［2］ Gan SY, Zhong XY, Xie SM, et al. Expression and significance of tumor drug resistance related proteins and betacatenin in esophageal squamous cell carcinoma［J］. Chin J Cancer, 2010, 29(3): 300-305. ［3］ Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome［J］. Cell, 1982, 31(1): 99-109. ［4］ Rijsewijk F, Schuermann M, Wagenaar E, et al. The drosophila homolog of the mouse mammary oncogene int1 is identical to the segment polarity gene wingless［J］. Cell, 1987, 50(4): 649-657. ［5］ Akiyama T. Wnt/betacatenin signaling［J］. Cytokine Growth Factor Rev, 2000, 11(4): 273-282. ［6］ Thomas DW. Bone and cancer［J］. J Pathol, 2010, 220(1): 1-4. ［7］ Ma Y, Ren Y, Han EQ, et al. Inhibition of the Wntβcatenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy［J］. Biochem Biophys Res Commun, 2013, 431(2): 274-279. DOI: 10.1016/j.bbrc.2012.12.118. ［8］ Zhang F, Chen A, Chen J, et al. SiRNAmediated silencing of betacatenin suppresses invasion and chemosensitivity to doxorubicin in MG63 osteosarcoma cells［J］. Asian Pac J Cancer Prev, 2011, 12(1): 239-245. ［9］ Zhang F, Chen A, Chen J, et al. Influence of βcatenin small interfering RNA on human osteosarcoma cells［J］. J Huazhong Univ Sci Technolog Med Sci, 2011, 31(3): 353-358. DOI: 10.1007/s11596-011-0380-9. ［10］ Morin PJ. Betacatenin signaling and cancer［J］. Bioessays, 1999, 21(12): 1021-1030. ［11］ Wang X, Wu X, Wang C, et al. Transcriptional suppression of breast cancer resistance protein (BCRP) by wildtype p53 through the NFkappaB pathway in MCF7 cells［J］. FEBS Lett, 2010, 584(15): 33923397. DOI: 10.1016/j.febslet.2010.06.033. ［12］ Zhang H, Zhang X, Wu X, et al. Interference of frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/βcatenin pathway［J］. Cancer Lett, 2012, 323(1): 106-113. DOI: 10.1016/j.canlet.2012.03.039. ［13］ Kildal W, Risberg B, Abeler VM, et al. Betacatenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients［J］. Eur J Cancer, 2005, 41(8): 1127-1134. DOI: 10.1016/j.ejca.2005.01.022. ［14］ Cai G, Wang J, Xin X, et al. Phosphorylation of glycogen synthase kinase3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells［J］. Int J Oncol, 2007, 31(3): 657-662. ［15］ Zhao H, Wei W, Sun Y, et al. Interference with the expression of βcatenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model［J］. DNA Cell Biol, 2015, 34(1): 55-62. DOI: 10.1089/dna.2014.2626. ［16］ He B, Barg RN, You L, et al. Wnt signaling in stem cells and nonsmallcell lung cancer［J］. Clin Lung Cancer, 2005, 7(1): 54-60. DOI: 10.3816/CLC.2005.n.022. ［17］ Gao Y, Liu Z, Zhang X, et al. Inhibition of cytoplasmic GSK3β increases cisplatin resistance through activation of Wnt/βcatenin signaling in A549/DDP cells［J］. Cancer Lett, 2013, 336(1): 231-239. DOI: 10.1016/j.canlet.2013.05.005. ［18］ Cheng H, Liang H, Qin Y, et al. Nuclear betacatenin overexpression in metastatic sentinel lymph node is associated with synchronous liver metastasis in colorectal cancer［J］. Diagn Pathol, 2011, 6: 109. DOI: 10.1186/1746-1596-6-109. ［19］万兵, 郑玉仙, 叶飞君. Wnt/βcatenin信号通路在肝癌耐药中的研究作用［J］. 中国综合临床, 2012, 28(12): 1242-1245. DOI: 10.3760/cma.j.issn.10086315.2012.12.004. ［20］ Xu N, Shen C, Luo Y, et al. Upregulated miR130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatintreated HCC cell［J］. Biochem Biophys Res Commun, 2012, 425(2): 468-472. DOI: 10.1016/j.bbrc.2012.07.127. ［21］ Shen DY, Zhang W, Zeng X, et al. Inhibition of Wnt/β-catenin signaling downregulates P-glycoprotein and reverses multidrug resistance of cholangiocarcinoma［J］. Cancer Sci, 2013, 104(10): 1303-1308. DOI: 10.1111/cas.12223. ［22］ Shen DY, Kang JH, Song W, et al. Apoptosis of human cholangiocarcinoma cell lines induced by β-escin through mitochondrial caspasedependent pathway［J］. Phytother Res, 2011, 25(10): 1519-1526. DOI: 10.1002/ptr.3435. ［23］ Huang GL, Shen DY, Cai CF, et al. βescin reverses multidrug resistance through inhibition of the GSK3β/βcatenin pathway in cholangiocarcinoma［J］. World J Gastroenterol, 2015, 21(4): 1148-1157. DOI: 10.3748/wjg.v21.i4.1148.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.